.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Express Scripts
Boehringer Ingelheim
Cipla
Citi
UBS
Moodys
Farmers Insurance
McKinsey
Federal Trade Commission

Generated: July 25, 2017

DrugPatentWatch Database Preview

FERRIPROX Drug Profile

« Back to Dashboard

Which patents cover Ferriprox, and what generic Ferriprox alternatives are available?

Ferriprox is a drug marketed by Apopharma Inc and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in twenty-five countries.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferiprone profile page.

Summary for Tradename: FERRIPROX

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list68
Clinical Trials: see list24
Patent Applications: see list504
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FERRIPROX at DailyMed

Pharmacology for Tradename: FERRIPROX

Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
SOLUTION;ORAL208030-001Sep 9, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Apopharma Inc
FERRIPROX
deferiprone
TABLET;ORAL021825-001Oct 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FERRIPROX

Drugname Dosage Strength RLD Submissiondate
deferiproneTablets500 mgFerriprox1/29/2016

International Patent Family for Tradename: FERRIPROX

Country Document Number Estimated Expiration
Cyprus1116146► Subscribe
Eurasian Patent Organization022751► Subscribe
Mexico2010011701► Subscribe
South Africa200109322► Subscribe
South Africa201008374► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Merck
Cipla
Dow
Express Scripts
Fish and Richardson
Deloitte
Farmers Insurance
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot